Show simple item record

Cancer treatment with polymer-bound cytostatic drugs and its potentiation through immunomodulation
dc.contributor.advisorKovář, Marek
dc.creatorChmelová, Helena
dc.date.accessioned2017-04-20T05:25:39Z
dc.date.available2017-04-20T05:25:39Z
dc.date.issued2009
dc.identifier.urihttp://hdl.handle.net/20.500.11956/24851
dc.description.abstractCancer treatment with polymer-bound cytostatic drugs and its potentiation through immunomodulation Poly[N-2-(hydroxypropyl)-methacrylamide] (PHPMA) is a synthetic water soluble and biocompatible polymer which can be used as a carrier of a cytostatic drug and an antibody as a targeting moiety. The antibody ensures the site-specific delivery of the conjugate. Nevertheless, even polymeric conjugates without any tumor-specific targeting moiety are passively accumulated within solid tumors via so called Enhanced Permeability and Retention (EPR) effect, in case that their molecular wight is at least 40 kDa. Antibody-targeted polymeric drugs have been shown previously to have a cytostatic activity in vitro and an antitumor activity in vivo. Since treatment of cancer diseases in practice is far from such ideal conditions and many tumors have no strictly specific marker suitable for targeted therapy, upgrading of the treatment efficacy represents the major challenge. One of the possible ways how to improve insufficient chemotherapy outcome can be using of a combination of polymer-bound cytostatic drug and potent immunomodulation able to induce a robust anti-cancer immune response. In this study, we have used B cell leukemia BCL1 as an experimental tumor model. BCL1 cells express surface IgM with an unique...en_US
dc.languageČeštinacs_CZ
dc.language.isocs_CZ
dc.publisherUniverzita Karlova, Přírodovědecká fakultacs_CZ
dc.titlePoužití imunomodulace pro potenciaci chemoterapie polymerními cytostatikycs_CZ
dc.typediplomová prácecs_CZ
dcterms.created2009
dcterms.dateAccepted2009-06-08
dc.description.departmentDepartment of Genetics and Microbiologyen_US
dc.description.departmentKatedra genetiky a mikrobiologiecs_CZ
dc.description.facultyFaculty of Scienceen_US
dc.description.facultyPřírodovědecká fakultacs_CZ
dc.identifier.repId52521
dc.title.translatedCancer treatment with polymer-bound cytostatic drugs and its potentiation through immunomodulationen_US
dc.contributor.refereeDrda Morávková, Alena
dc.identifier.aleph001222579
thesis.degree.nameMgr.
thesis.degree.levelnavazující magisterskécs_CZ
thesis.degree.disciplineGenetika, molekulární biologie a virologiecs_CZ
thesis.degree.disciplineGenetics, Molecular Biology and Virologyen_US
thesis.degree.programBiologiecs_CZ
thesis.degree.programBiologyen_US
uk.thesis.typediplomová prácecs_CZ
uk.taxonomy.organization-csPřírodovědecká fakulta::Katedra genetiky a mikrobiologiecs_CZ
uk.taxonomy.organization-enFaculty of Science::Department of Genetics and Microbiologyen_US
uk.faculty-name.csPřírodovědecká fakultacs_CZ
uk.faculty-name.enFaculty of Scienceen_US
uk.faculty-abbr.csPřFcs_CZ
uk.degree-discipline.csGenetika, molekulární biologie a virologiecs_CZ
uk.degree-discipline.enGenetics, Molecular Biology and Virologyen_US
uk.degree-program.csBiologiecs_CZ
uk.degree-program.enBiologyen_US
thesis.grade.csVýborněcs_CZ
thesis.grade.enExcellenten_US
uk.abstract.enCancer treatment with polymer-bound cytostatic drugs and its potentiation through immunomodulation Poly[N-2-(hydroxypropyl)-methacrylamide] (PHPMA) is a synthetic water soluble and biocompatible polymer which can be used as a carrier of a cytostatic drug and an antibody as a targeting moiety. The antibody ensures the site-specific delivery of the conjugate. Nevertheless, even polymeric conjugates without any tumor-specific targeting moiety are passively accumulated within solid tumors via so called Enhanced Permeability and Retention (EPR) effect, in case that their molecular wight is at least 40 kDa. Antibody-targeted polymeric drugs have been shown previously to have a cytostatic activity in vitro and an antitumor activity in vivo. Since treatment of cancer diseases in practice is far from such ideal conditions and many tumors have no strictly specific marker suitable for targeted therapy, upgrading of the treatment efficacy represents the major challenge. One of the possible ways how to improve insufficient chemotherapy outcome can be using of a combination of polymer-bound cytostatic drug and potent immunomodulation able to induce a robust anti-cancer immune response. In this study, we have used B cell leukemia BCL1 as an experimental tumor model. BCL1 cells express surface IgM with an unique...en_US
uk.publication.placePrahacs_CZ
uk.grantorUniverzita Karlova, Přírodovědecká fakulta, Katedra genetiky a mikrobiologiecs_CZ
dc.identifier.lisID990012225790106986


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


© 2017 Univerzita Karlova, Ústřední knihovna, Ovocný trh 560/5, 116 36 Praha 1; email: admin-repozitar [at] cuni.cz

Za dodržení všech ustanovení autorského zákona jsou zodpovědné jednotlivé složky Univerzity Karlovy. / Each constituent part of Charles University is responsible for adherence to all provisions of the copyright law.

Upozornění / Notice: Získané informace nemohou být použity k výdělečným účelům nebo vydávány za studijní, vědeckou nebo jinou tvůrčí činnost jiné osoby než autora. / Any retrieved information shall not be used for any commercial purposes or claimed as results of studying, scientific or any other creative activities of any person other than the author.

DSpace software copyright © 2002-2015  DuraSpace
Theme by 
@mire NV